GlassScriptPhysician profile
Ira J Sutton
NPI 1720193691
$3,122.93
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $725 · 2021: $800 · 2022: $391 · 2023: $290 · 2024: $31.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $358.13 | 2019-2024 | Wegovy, Saxenda, Ozempic |
| Janssen Pharmaceuticals, INC | $339.80 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $315.40 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $293.66 | 2019-2024 | Farxiga |
| Pfizer INC. | $265.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $251.55 | 2019-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.97 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $183.51 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.63 | 2019-2023 | Camzyos |
| Abbvie INC. | $96.94 | 2021 | |
| Exact Sciences Corporation | $75.23 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $75.22 | 2020 | |
| Merck Sharp & Dohme LLC | $74.38 | 2021-2022 | |
| Abbott Laboratories | $68.71 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $67.67 | 2022-2023 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $59.19 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $49.38 | 2021 | |
| Allergan, INC. | $35.25 | 2020 | |
| Sanofi Pasteur INC. | $35.05 | 2020-2021 | |
| Esperion Therapeutics, INC. | $25.00 | 2020 | |
| Eisai INC. | $19.55 | 2021 | |
| Boston Scientific Corporation | $19.26 | 2021 | |
| Dexcom, INC. | $19.04 | 2021 | |
| Horizon Therapeutics Plc | $16.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.44 | 2019 | |
| Seqirus USA INC | $14.34 | 2019 | |
| Genentech USA, INC. | $14.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.